Johnson & Johnson Website, Blog & Press Pages

Johnson & Johnson Website, Blog & Press Pages - aVenture

Johnson & Johnson - Library

jnj.comCrawled Oct 15, 2026

Press

6 pages

Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for the Development of a Treatment for Chronic Graft-Versus-Host Disease (cGVHD)/media-center/press-releases/ibrutinib-imbruvica-granted-breakthrough-therapy-designiation-by-us-food-and-drug-administration-fda-for-the-development-of-a-treatment-for-chronic-graft-versus-host-disease-chvhd
- In current clinical practice, there are no FDA-approved treatments for this life-threatening condition - FDA designation suggests potential use of ibrutinib beyond hematologic malignancies - The FDA also granted ibrutinib orphan drug designation for cGVHD
INCIVO (Telaprevir) Approved In Europe Offering Higher Cure Rates For Genotype-1 Chronic Hepatitis C Compared To Standard Treatment/media-center/press-releases/incivo-telaprevir-approved-in-europe-offering-higher-cure-rates-for-genotype-1-chronic-hepatitis-c-compared-to-standard-treatment
New treatment options increase chance of a cure
Janssen Presents New Data Showing INVOKANA (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors/media-center/press-releases/janssen-presents-new-data-showing-invokana-canagliflozin-is-associated-with-greater-blood-glucose-control-and-treatment-adherence-compared-to-dpp-4-inhibitors
Other Presentations at American Diabetes Association Scientific Sessions Show INVOKANA Therapy also is Associated with Achieving Blood Glucose and Blood Pressure Treatment Goals
New Study Suggests Tapentadol IR For Acute Pain is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR/media-center/press-releases/new-study-suggests-tapentadol-ir-for-acute-pain-is-associated-with-improved-gastrointestinal-tolerability-compared-to-oxycodone-ir
The report describes tapentadol as a centrally acting oral analgesic and says it provided pain relief with fewer gastrointestinal side effects.

Team

6 pages

Jennifer A. Doudna, Ph.D./leadership/jennifer-a-doudna
Independent Director since 2018
Jennifer Taubert/leadership/jennifer-taubert
John C. Reed, M.D., Ph.D./leadership/john-reed
Dr. Hait is Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Johnson & Johnson Executive Committee.
Marillyn A. Hewson/leadership/marillyn-a-hewson
The page covers Marillyn A. Hewson’s role at Johnson & Johnson and contributions to the company’s growth.

Contact

1 page

Homepage

1 page

Homepage/
The company aims to prevent and cure complex diseases, provide smarter and less invasive treatments, and develop personal solutions.

Privacy

1 page

Mhmda/privacy-policy/mhmda
This CHD Privacy Notice supplements the J&J Privacy Policy and applies specifically to “Consumers” as defined under Washington’s My Health My Data Act (“MHMDA”).

Coverage

1 item

Cramer’s week ahead: Earnings kick off as banks and chipmakers face big testscnbc.com/2026/10/09/jim-cramer-week-ahead-bank-earnings-ai-chips.html
Jim Cramer says the coming earnings season will give investors a clearer view of corporate performance and the artificial intelligence trade. Major banks report Tuesday, followed by ASML, Bank of America, Morgan Stanley and BlackRock on Wednesday; Taiwan Semiconductor Manufacturing reports Thursday, alongside inflation and retail sales data. Cramer sees possible opportunities in some bank and semiconductor stocks but warns that rising bond yields remain a significant market risk.
Oct 2026 · CNBC TechNews article